15 . June , 2019 - Saturday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Cisplatin

Big Image Pronouncation: (SIS-plat-in)
Class: Platinum coordination complex

Trade Names:
Platinol AQ
- Solution for injection 1 mg/mL
- Powder for injection 1 mg/mL

Mechanism of Action


The antitumor effect of cisplatin has been correlated with binding to DNA, production of intrastrand crosslinks, and formation of DNA adducts.



Vd is about 11 to 12 L/m 2 (steady state). Platinum is 90% protein bound. Cisplatin is excreted in breast milk.


The t ½ is about 20 to 30 min (cisplatin) and at least 5 days (platinum-albumin complexes). Cl is about 15 to 16 L/h/m 2 . Renal Cl is 50 to 62 mL/min/m 2 . Cisplatin is 90% excreted in urine and less than 10% removed by biliary excretion.

Indications and Usage

Metastatic testicular or ovarian tumors, advanced bladder cancer.

Unlabeled Uses

Squamous cell carcinoma of the head and neck and of the cervix; lung carcinomas, osteogenic sarcoma, brain tumors; advanced esophageal, adrenal cortex, breast, endometrial, and liver carcinoma, bone marrow transplantation.


Pre-existing renal impairment; myelosuppression; hearing impairment; history of allergic reactions to cisplatin or other platinum-containing compounds.

Dosage and Administration

Metastatic Testicular Tumors

IV Cisplatin 20 mg/m 2 /day IV for 5 days every 3 wk for 3 courses (combination regimen). Single doses of cisplatin up to 120 mg/m 2 in combination with other antineoplastics have been used.

Metastatic Ovarian Tumors (Cyclophosphamide Combination Therapy)

IV Cisplatin 75 to 100 mg/m 2 once every 4 wk. Cyclophosphamide 600 mg/m 2 once every 4 wk (day 1).

Metastatic Ovarian Tumors (Single Agent Therapy)

IV Administer as a single agent of 100 mg/m 2 IV/cycle once every 4 wk.

Advanced Bladder Cancer

IV Administer as a single agent. Give 50 to 70 mg/m 2 once every 3 to 4 wk, depending on prior radiation therapy or chemotherapy. For heavily pretreated patients, give an initial dose of 50 mg/m 2 /cycle repeated every 4 wk.

Repeat Courses

IV Do not give a repeat course until serum creatinine is below 1.5 mg/dL or BUN is below 25 mg/dL or until circulating blood elements are at an acceptable level (platelets at least 100,000/mm 3 , WBC at least 4,000/mm 3 ). Do not give subsequent doses until an audiometric analysis indicates that auditory acuity is within normal limits.

Renal Impairment

IV The manufacturer does not recommend the use of cisplatin in patients with renal impairment. Some clinicians recommend not giving cisplatin to patients with a Ccr below 30 mL/min.

General Advice

  • If not protected from light, reconstituted cisplatin solution is stable for 6 h at room temperature.
  • Cisplatin degrades and forms a black precipitate on contact with aluminum. Although needles and administration sets rarely contain aluminum, consider this interaction if a black precipitate is observed.
  • Reconstitute powder with 50 mL of sterile Water for Injection or Bacteriostatic Water for Injection for a final concentration of 1 mg/mL. The resulting solution should be clear and colorless.
  • Skin reactions associated with accidental exposure may occur. Use gloves. If solution contacts skin or mucosa, wash immediately and thoroughly with soap and water and flush mucosa with water.
  • The manufacturer recommends further dilution in 2 L of solution containing 37.5 g mannitol, using dextrose 5% with sodium chloride 0.45%. More concentrated solutions, up to a max concentration of 0.7 mg/mL have been used. Cisplatin (up to 200 mg) may also be diluted in 500 mL of sodium chloride 0.9% with 12.5 to 25 g mannitol.
  • The administration of cisplatin using a 6- to 8-h infusion with IV hydration and mannitol has been used to reduce nephrotoxicity.
  • Delayed emesis typically occurs 24 to 72 h after cisplatin administration. Severity may be reduced by administration of a prophylactic regimen of dexamethasone in combination with metaclopramide or prochlorperazine. Begin prophylactic therapy 16 to 24 h after cisplatin administration and continue for a total of 4 days. Add additional antiemetics if breakthrough nausea and vomiting occur.


  • Store at 59° to 77°F. Protect unopened container from light. Do not refrigerate. The cisplatin remaining in the amber vial following initial entry is stable for 28 days protected from light or for 7 days under fluorescent room light.
  • Cisplatin powder reconstituted with Bacteriostatic Water for Injection is chemically stable for 3 days at room temperature with protection from light.
  • Cisplatin and fluorouracil admixtures are stable in normal saline 0.9% for 1 h.

Drug Interactions


Potentiation of nephrotoxicity is possible.


Cisplatin may transiently decrease lithium serum levels.

Loop diuretics (eg, furosemide)

Potentiation of ototoxicity is possible.


Paclitaxel clearance decreases when cisplatin is given immediately prior to paclitaxel, resulting in increased hematologic toxicity.


Cisplatin may decrease absorption or increase metabolism, resulting in lower serum levels of phenytoin.

Laboratory Test Interactions

None well documented.

Adverse Reactions


MI; cerebrovascular accident; cerebral arteritis; thrombotic microangiopathy.


Peripheral sensory neuropathy with a glove-and-stocking distribution.


Nausea; vomiting; anorexia; transient LFT elevations.


Bone marrow suppression.


Anaphylactic reaction.


Hypomagnesemia; hypocalcemia; hypokalemia; SIADH.


Dose-related and cumulative renal tubular damage.

Special Senses

Tinnitus; high frequency hearing loss.



Overdose/confusion with carboplatin

Doses above 100 mg/m 2 /cycle once every 3 to 4 wk rarely used. Avoid confusion with carboplatin or prescribing practices that fail to differentiate daily doses from total dose per cycle.


Marked nausea and vomiting occur in almost all patients and are occasionally so severe that the drug must be discontinued.


Myelosuppression occurs in 25% to 30% of patients. Leukopenia and thrombocytopenia are more pronounced at doses above 50 mg/m 2 . Anemia (decrease of 2 g hemoglobin/dL) occur at the same frequency and with the same timing as leukopenia and thrombocytopenia.


Anaphylactic-like reactions have occurred.


Has occurred in no more than 31% of patients given a single dose of 50 mg/m 2 . It is manifested by tinnitus or loss of high frequency hearing, and occasionally deafness. May be pronounced in children.

Renal toxicity

Dose-related and cumulative renal insufficiency is the major dose-limiting toxicity. This is manifested by elevations in BUN and creatinine, serum uric acid, or a decrease in Ccr. Renal toxicity becomes more severe and prolonged with repeated courses; therefore, renal function must return to normal before another dose can be given. Amifostine can be used to reduce renal toxicity in patients with advanced ovarian cancer receiving repeated doses of cisplatin.


Category D .


Reported to be found in breast milk. Do not breast-feed.


Safety and efficacy not established.

Electrolyte disturbances

Hypomagnesemia, hypocalcemia, hyponatremia, hypokalemia, and hypophosphatemia have occurred and are probably related to renal tubular damage.

Extravasation risk

Local irritation or phlebitis may occur. Refer to your institution specific protocol.


Transient elevations of liver enzymes, especially AST, as well as bilirubin have been reported.

High/Cumulative doses

Muscle cramps, defined as localized painful, involuntary skeletal muscle contractions of sudden onset and short duration, have occurred.


Occurs at about the same frequency as increase in BUN and serum creatinine. It is more pronounced after doses above 50 mg/m 2 . Monitor serum uric acid. Minimize effects with hydration, urinary alkalinization, and allopurinol.


Neurotoxicity, usually characterized by peripheral neuropathy, have occurred. Severe neuropathies have occurred in patients receiving higher doses of cisplatin or greater dose frequencies than those recommended, or after prolonged therapy. Discontinue therapy when symptoms are observed.

Ophthalmic effects

Optic neuritis, papilledema, and cerebral blindness have occurred infrequently in patients receiving recommended cisplatin doses.

Vascular toxicities

These events are rare and coincident with the use of cisplatin in combination with other antineoplastic agents. These events may include MI, cerebrovascular accident, thrombotic microangiopathy, or cerebral arteritis.



Kidney failure, liver failure, deafness, ocular toxicity, significant myelosuppression, intractable nausea and vomiting, neuritis, death.

Patient Information

  • Advise patient, family, or caregiver that medication will be prepared and administered by health care provider in a health care setting.
  • Advise patient, family, or caregiver that medication may be used in combination with other agents to achieve maximum benefit possible.
  • Review dosing schedule with patient, family, or caregiver.
  • Advise patient, family, or caregiver to immediately report any of the following to health care provider: rash; hives; difficulty breathing; fever, chills or other signs of infection; sores in mouth; unusual bleeding or bruising.
  • Advise patient, family, or caregiver to report any of the following to health care provider: persistent nausea, vomiting or appetite loss; persistent or worsening general body weakness; changes in hearing or ringing in the ears; dizziness or feeling of whirling motion; abnormal skin sensations; any other unexplained sensation; pain, redness or swelling at injection site.

Recent Drug Updates at DrugIndexOnline:

AccuHist PDX Syrup AccuHist PDX Syrup
Generic Name: brompheniramine, dextromethorphan, guaifenesin, and phenylephrine (brom fen EER a meen, dex tro me THOR fan, gwye FEN e sin, fen il EFF rin) Brand Names: AccuHist PDX Syrup, Allanhist PDX Syrup, Bromhist-PDX, Uni-Hist PDX Syrup What is AccuHist PDX Syrup (brompheniramine, d more...

Azithromycin Tablets Azithromycin Tablets
Generic Name: Azithromycin Tablets (az-ith-roe-MYE-sin) Brand Name: ZithromaxAzithromycin is used for:Treating mild to moderate infections caused by certain bacteria. It may also be used alone or in combination with other medicines to treat or prevent certain infections in persons with advanced more...

Cabergoline Cabergoline
Generic Name: Cabergoline (ka-BER-goe-leen) Brand Name: DostinexCabergoline is used for:Treating disorders associated with high levels of the hormone prolactin, either due to tumors in the pituitary gland or to unknown causes. It may also be used for other conditions as determined by your docto more...

Enulose Enulose
Generic Name: lactulose (LACK too lohss) Brand Names: Cephulac, Chronulac, Constulose, Duphalac, Enulose What is Enulose (lactulose)? Lactulose is a type of sugar. It is broken down into mild acids in the colon (the end part of the intestinal tract). These acids draw water into the colo more...

Gelhist Pediatric Gelhist Pediatric
Generic Name: chlorpheniramine, pyrilamine, and phenylephrine (klor feh NEER a meen, pie RIH la meen, feh nill EH frin) Brand Names: Atrohist Pediatric, Equitan Pediatric, Gelhist Pediatric, Histatan, R-Tannamine, R-Tannate, Rhinatate, Tanamine, Tanoral, Triotann, Triotann-S, Tritan, URL- more...

Mycostatin Suspension Mycostatin Suspension
Generic Name: Nystatin Oral Suspension (nye-STA-tin) Brand Name: MycostatinMycostatin Suspension is used for:Treatment of fungal infections of the mouth. It may also be used for other conditions as determined by your doctor. Mycostatin Suspension is an antifungal. It works by weakening cell memb more...

Pima Pima
Some commonly used brand names are: In the U.S.— Pima In Canada— Thyro-Block * Generic name product may be available in the U.S. Other commonly used names are KI and SSKI . * Not commercially available in the U.S.; however, potassium iodide tablets are available to governme more...

Pred Mild Ophthalmic Pred Mild Ophthalmic
Some commonly used brand names are: In the U.S.— AK-Dex 2 AK-Pred 6 AK-Tate 6 Baldex 2 Decadron 2 Dexair 2 Dexotic 2 Econopred 6 Econopred Plus 6 Eflone 3 Flarex 3 Fluor-Op 3 FML Forte 3 FML Liquifilm 3 FML S.O.P. 3 HMS Liquifilm 5 Inflamase Forte 6 Inflamase Mild 6 I-Pred 6 Lite Pred 6 M more...